Equities Analysts Issue Forecasts for ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research report issued on Tuesday, January 14th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn ($2.50) per share for the year, up from their previous forecast of ($2.52). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($3.16) EPS, Q1 2026 earnings at $0.34 EPS, Q2 2026 earnings at $0.11 EPS and FY2026 earnings at $1.74 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the prior year, the company posted $1.15 EPS. The firm’s revenue was down 33.3% compared to the same quarter last year.

A number of other analysts have also recently weighed in on ALNY. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Bank of America lifted their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Sanford C. Bernstein reduced their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Raymond James raised their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Trading Down 1.2 %

ALNY opened at $246.27 on Friday. The company’s 50 day moving average is $246.62 and its 200-day moving average is $259.70. The company has a market cap of $31.76 billion, a P/E ratio of -94.00 and a beta of 0.34. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock worth $2,540,455 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Traynor Capital Management Inc. raised its holdings in Alnylam Pharmaceuticals by 29.0% during the fourth quarter. Traynor Capital Management Inc. now owns 9,350 shares of the biopharmaceutical company’s stock worth $2,200,000 after buying an additional 2,101 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 15.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 13,317 shares of the biopharmaceutical company’s stock worth $3,134,000 after acquiring an additional 1,789 shares during the last quarter. Perpetual Ltd raised its holdings in shares of Alnylam Pharmaceuticals by 117.2% in the 4th quarter. Perpetual Ltd now owns 8,931 shares of the biopharmaceutical company’s stock worth $2,102,000 after acquiring an additional 4,819 shares during the last quarter. Sara Bay Financial lifted its position in Alnylam Pharmaceuticals by 31.3% in the 4th quarter. Sara Bay Financial now owns 985 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 235 shares in the last quarter. Finally, Merit Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $587,000. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.